Our NephJC STOP-ACEi editorial in Kidney Medicine is live. Great work from Susan Thanabalasingam and Cristina Popa, supported by Nayan, Swap, and Jade.
Read it here.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
Our NephJC STOP-ACEi editorial in Kidney Medicine is live. Great work from Susan Thanabalasingam and Cristina Popa, supported by Nayan, Swap, and Jade.
Read it here.
Episode 055: The Filtrate try to figure out STOP ACE with the assistance of Laurie Tomlinson.
If you missed the latest NephJC discussion, at least read the highlights here.
You gotta know when to hold’em and know when to fold’em. Review the #TenTweetNephJC for the STOP ACEi Trial, and always hold onto your ACEi.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) December 1, 2022
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/n8dcopDLPT
Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD? NSMC Intern Dana Larsen explains it graphically.